DAGLA

Across TCGA pan-cancer cohorts, DAGLA Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DAGLA data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher DAGLA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DAGLA expression acts as an unfavorable survival marker.

LAML, HNSC, and SKCM are the cancer types where DAGLA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.082	0.582	.004	12	view →
HNSC	OS	Median	IV	0.087	0.733	<.001	12	view →
SKCM	OS	Median	III,IV	0.140	0.408	.009	9	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.395	0.788	.003	6	view →
SARC	DFS	Median	All	0.109	0.632	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DAGLA–LAML (DFS)

Open the LAML breakdown →